Notícias e Atividades da Actinium Pharmaceuticals
Presença
Sede: Estados Unidos
Actinium Pharmaceuticals é uma empresa listada sob o símbolo ATNM (US).
Executivos
Veja o organograma con seus 15 executivos principais
Biografias mais buscadas da Actinium Pharmaceuticals
- Sandesh Seth, Chairman of the Board and Chief Executive Officer
- David Nicholson, Lead Independent Director
- Ajit Shetty, Director
Recentes movimentos de executivos em Actinium Pharmaceuticals
- Steffen Heeger, ingressou na Companhia como Chief Medical Officer (Notícia publicada em 1 de junho de 2026).
- Steve O'Loughlin, Chief Financial Officer, deixou a Companhia (Notícia publicada em 4 de março de 2026).
Criar um alerta
para seguir os movimentos de executivos da Actinium Pharmaceuticals.
Farmacêutica
Actinium Pharmaceuticals possui 1.920 concorrentes concorrentes Sanofi (França), Moderna (Estados Unidos) e Eli Lilly (Estados Unidos).
Popular M&A news in Farmacêutica
- Eli Lilly has announced the acquisition of AtaiBeckley (publicado em 17 de julho de 2026).
- Agenus acaba de anunciar uma arrecadação de fundos de 340 milhões de dólares. (publicado em 17 de julho de 2026).
- GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Actinium Pharmaceuticals
- Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting :: Actinium Pharmaceuticals, In
- Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting :: Actinium Pharmaceuticals, Inc. (ATNM)
- Press Releases :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cance
- Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium :: Actinium P
- Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications :: Actinium Pharmaceuticals,
- Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference :: Actinium Pharmaceuticals, Inc. (ATNM)
- View more press releases Close
Redes sociais sobre Actinium Pharmaceuticals
- Actinium Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Actinium Pharmaceuticals na LinkedIn, X (Twitter) e YouTube
